Dr. Reddy's Laboratories Agreed To Partially Defer A Milestone Payment From Citius Oncology, Inc., Due On September 9, 2024, Upon FDA Approval Of LYMPHIR, Without Penalty, Pending Further Discussions, As Per Their 2021 Asset Purchase Agreement
Dr. Reddy's Laboratories Agreed To Partially Defer A Milestone Payment From Citius Oncology, Inc., Due On September 9, 2024, Upon FDA Approval Of LYMPHIR, Without Penalty, Pending Further Discussions, As Per Their 2021 Asset Purchase Agreement
Pending further discussions with Dr. Reddy's Laboratories SA, a subsidiary of Dr. Reddy's Laboratories, Ltd. (collectively, "Dr. Reddy's"), Dr. Reddy's agreed to a partial deferral without penalty of a milestone payment by Citius Oncology, Inc. (the "Company"), which was triggered upon regulatory approval of LYMPHIRTM by the U.S. Food and Drug Administration and due on September 9, 2024, pursuant to the terms of the Asset Purchase Agreement, dated as of September 1, 2021, between Dr. Reddy's and Citius Pharmaceuticals, Inc. (the "Asset Purchase Agreement").
在与Dr. Reddy's Laboratories SA工作室的进一步讨论后，Dr. Reddy's同意对Citius Oncology, Inc.（以下简称"公司"）的一笔里程碑支付进行部分延期，延期期间没有罚金。该里程碑支付是根据2021年9月1日Dr. Reddy's和Citius Pharmaceuticals, Inc.之间的资产购买协议（以下简称"购买协议"）的条款，在LYMPHIRTm获得美国食品和药物管理局的监管批准后触发，并且应于2024年9月9日到期。
